116 related articles for article (PubMed ID: 3014110)
21. Duration of angiotensin-converting enzyme inhibition: implications for tolerability.
Murray NH
Cardiology; 1991; 79 Suppl 1():22-9. PubMed ID: 1655262
[TBL] [Abstract][Full Text] [Related]
22. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats.
Lin JH; Chen IW; Ulm EH; Duggan DE
Drug Metab Dispos; 1988; 16(3):392-6. PubMed ID: 2900730
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function.
Hayes PC; Plevris JN; Bouchier IA
J Hum Hypertens; 1989 Jun; 3 Suppl 1():153-8. PubMed ID: 2550638
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of angiotensin converting enzyme from sheep tissues by captopril, lisinopril and enalapril.
Udupa EG; Rao NM
Indian J Biochem Biophys; 1997 Dec; 34(6):524-8. PubMed ID: 9594434
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin converting enzyme inhibitors. Disparities in the mechanism of their antihypertensive effect.
Garavaglia GE; Messerli FH; Nunez BD; Schmieder RE; Frohlich ED
Am J Hypertens; 1988 Jul; 1(3 Pt 3):214S-216S. PubMed ID: 2843195
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril.
Ajayi AA; Campbell BC; Kelman AW; Howie C; Meredith PA; Reid JL
Int J Clin Pharmacol Res; 1985; 5(6):419-27. PubMed ID: 3005181
[TBL] [Abstract][Full Text] [Related]
27. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of rabbit lung angiotensin-converting enzyme by N alpha-[(S)-1-carboxy-3-phenylpropyl]L-alanyl-L-proline and N alpha-[(S)-1-carboxy-3-phenylpropyl]L-lysyl-L-proline.
Bull HG; Thornberry NA; Cordes MH; Patchett AA; Cordes EH
J Biol Chem; 1985 Mar; 260(5):2952-62. PubMed ID: 2982845
[TBL] [Abstract][Full Text] [Related]
29. Stability and in vitro absorption of captopril, enalapril and lisinopril across the rat intestine.
Zhou XH; Li Wan Po A
Biochem Pharmacol; 1994 Mar; 47(7):1121-6. PubMed ID: 8161340
[TBL] [Abstract][Full Text] [Related]
30. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum.
Lecocq B; Funck-Brentano C; Lecocq V; Ferry A; Gardin ME; Devissaguet M; Jaillon P
Clin Pharmacol Ther; 1990 Mar; 47(3):397-402. PubMed ID: 2311339
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of lisinopril in older patients with essential hypertension.
Gomez HJ; Smith SG; Moncloa F
Am J Med; 1988 Sep; 85(3B):35-7. PubMed ID: 2844085
[TBL] [Abstract][Full Text] [Related]
32. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses.
Uretsky BF; Shaver JA; Liang CS; Amin D; Shah PK; Levine TB; Walinsky P; LeJemtel T; Linnemeier T; Rush JE
Am Heart J; 1988 Aug; 116(2 Pt 1):480-8. PubMed ID: 2840815
[TBL] [Abstract][Full Text] [Related]
33. [The value of lysinopril in cardiac insufficiency].
Lambert M; Luccioni R
Rev Prat; 1990 Oct; 40(23 Suppl):53-8. PubMed ID: 2176346
[TBL] [Abstract][Full Text] [Related]
34. Effect of food on the bioavailability of pentopril, an angiotensin-converting-enzyme inhibitor, in healthy subjects.
Rakhit A; Hurley ME; Redalieu E; Kochak G; Tipnis V; Coleman J; Rommel A
J Clin Pharmacol; 1985 Sep; 25(6):424-8. PubMed ID: 2997306
[TBL] [Abstract][Full Text] [Related]
35. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis.
Kelly JG; Doyle GD; Carmody M; Glover DR; Cooper WD
Br J Clin Pharmacol; 1988 Dec; 26(6):781-6. PubMed ID: 2853960
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function.
van Schaik BA; Geyskes GG; van der Wouw PA; van Rooij HH; Porsius AJ
Eur J Clin Pharmacol; 1988; 34(1):61-5. PubMed ID: 2834209
[TBL] [Abstract][Full Text] [Related]
38. Lisinopril and ramiprilat protection of the vascular endothelium against free radical-induced functional injury.
Gillis CN; Chen X; Merker MM
J Pharmacol Exp Ther; 1992 Jul; 262(1):212-6. PubMed ID: 1320684
[TBL] [Abstract][Full Text] [Related]
39. A comparison of single doses of lisinopril and enalapril in hypertension.
Dews I; Wiseman WT; al-Khawaja I; Stephens J; VandenBurg M
J Hum Hypertens; 1989 Jun; 3 Suppl 1():35-9. PubMed ID: 2550644
[TBL] [Abstract][Full Text] [Related]
40. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension.
Whelton A; Dunne B; Glazer N; Kostis JB; Miller WE; Rector DJ; Tresznewsky ON
J Hum Hypertens; 1992 Aug; 6(4):325-31. PubMed ID: 1331444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
